文献速递淋巴瘤

新一代BTK抑制剂泽布替尼治疗边缘区淋巴瘤应答的分子关联研究

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

这项澳大利亚白血病与淋巴瘤组的转化研究利用组织全外显子测序和循环肿瘤游离DNA,分析MAGNOLIA试验中边缘区淋巴瘤患者对泽布替尼的原发性和获得性分子应答与耐药决定因素。18例患者基线肿瘤样本行全外显子测序,7例用定制48基因杂交捕获二代测序检测ctDNA。MYD88或TNFAIP3突变与无进展生存期改善相关,KMT2D突变有更差无进展生存期趋势;2例疾病进展患者检出获得性PLCG2和BTK突变。

要点

  • 18例基线样本中16例(89%)涉及NF-κB、NOTCH或BCR通路基因突变。
  • MYD88或TNFAIP3突变与无进展生存期改善相关,KMT2D突变有更差无进展生存期趋势。
  • 2例进展患者检出获得性PLCG2(R665W/R742P)和BTK(C481Y/C481F)突变。

核心结论

  • MYD88、TNFAIP3和KMT2D突变与接受泽布替尼治疗的复发/难治性边缘区淋巴瘤患者的无进展生存期相关。
  • 治疗中通过ctDNA检测获得性BTK和PLCG2突变是可行的,并可能预示临床疾病进展。

研究设计与样本

  • 澳大利亚白血病与淋巴瘤组转化研究,纳入MAGNOLIA临床试验中接受泽布替尼治疗的边缘区淋巴瘤患者。
  • 对18例患者基线肿瘤样本行全外显子测序,对7例患者用定制48基因杂交捕获二代测序检测ctDNA。
  • 体细胞突变与客观缓解数据用Fisher精确检验相关,生存分析用Kaplan-Meier法(log-rank检验)。
  • 该试验在https://anzctr.org.au/注册,注册号为#ACTRN12619000024145。

主要发现

  • 基线全外显子测序在48个优先基因中的33个(69%)检出突变。
  • 18例样本中16例(89%)涉及NF-κB、NOTCH或B细胞受体通路基因突变。
  • KMT2D突变(n=11)最常见,其次为FAT1(n=9)、NOTCH1、NOTCH2、TNFAIP3(n=5)和MYD88(n=4)突变。
  • 2例疾病进展患者检出获得性耐药突变PLCG2(R665W/R742P)和BTK(C481Y/C481F)。
  • 1例泽布替尼难治患者治疗前检出BTK E41K非催化性激活突变。

关键数值与推荐

  • MYD88或TNFAIP3突变与无进展生存期改善相关。
  • KMT2D突变有更差无进展生存期趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Using tissue whole exome sequencing (WES) and circulating tumor cell-free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response and resistance of marginal zone lymphoma (MZL) to zanubrutinib for patients treated in the MAGNOLIA clinical trial. WES was performed on baseline tumor samples obtained from 18 patients. For 7 patients, ctDNA sequence was interrogated using a bespoke hybrid-capture next-generation sequencing assay for 48 targeted genes. Somatic mutations were correlated with objective response data and survival analysis using Fisher exact test and Kaplan-Meier (log-rank) method, respectively. Baseline WES identified mutations in 33 of 48 (69%) prioritized genes. NF-κB, NOTCH, or B-cell receptor (BCR) pathway genes were implicated in samples from 16 of 18 patients (89%). KMT2D mutations (n = 11) were most common, followed by FAT1 (n = 9), NOTCH1, NOTCH2, TNFAIP3 (n = 5), and MYD88 (n = 4) mutations. MYD88 or TNFAIP3 mutations correlated with improved progression-free survival (PFS). KMT2D mutations trended to worse PFS. Acquired resistance mutations PLCG2 (R665W/R742P) and BTK (C481Y/C481F) were detected in 2 patients whose disease progressed. A BTK E41K noncatalytic activating mutation was identified before treatment in 1 patient who was zanubrutinib-refractory. MYD88, TNFAIP3, and KMT2D mutations correlate with PFS in patients with relapsed/refractory MZL treated with zanubrutinib. Detection of acquired BTK and PLCG2 mutations in ctDNA while on therapy is feasible and may herald clinical disease progression. This trial was registered at https://anzctr.org.au/ as #ACTRN12619000024145.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tatarczuch M, Waltham M, Shortt J, et al. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma. Blood Adv. 2023. PMID: 36947202. doi:10.1182/bloodadvances.2022009412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。